Overview

Adenomyosis and Ulipristal Acetate

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

Evaluation of efficiency of selective progesterone receptor modulators (SPRM) (Ulipristal acetate) on bleeding control and pain for patients with adenomyosis and wish to keep fertility.

Phase:

Phase 2

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborator:

Gedeon Richter Ltd.

Treatments:

Ulipristal acetate